Capital Group Investment Management Boosts Amgen Stake

The firm increased its holding in the biotech company by 93.4% in the third quarter.

Published on Mar. 10, 2026

Got story updates? Submit your updates here. ›

Capital Group Investment Management PTE. LTD. grew its position in Amgen Inc. (NASDAQ:AMGN) by 93.4% in the 3rd quarter, according to the company's recent 13F filing with the Securities and Exchange Commission (SEC). The firm now owns 11,732 shares of the medical research company's stock, worth $3,311,000 as of the filing.

Why it matters

This move by Capital Group Investment Management, a major institutional investor, suggests they see continued growth potential in Amgen's business and stock. Amgen is a leading biotech firm focused on developing innovative therapies for serious illnesses.

The details

Capital Group Investment Management increased its Amgen holdings by adding 5,666 shares during the third quarter. The firm now owns a total of 11,732 Amgen shares. Amgen's stock has seen strong performance, rising from a 52-week low of $261.43 to a high of $391.29 over the past year.

  • Capital Group Investment Management filed its 13F report for the 3rd quarter of 2026 on March 10, 2026.

The players

Capital Group Investment Management PTE. LTD.

A major institutional investment firm that manages a portfolio of stocks, including a significant position in Amgen.

Amgen Inc.

A global biotechnology company that focuses on discovering, developing, manufacturing and delivering human therapeutics to treat serious illnesses.

Got photos? Submit your photos here. ›

The takeaway

Capital Group's increased stake in Amgen suggests the firm sees continued growth potential in the biotech company, which has a portfolio of innovative therapies targeting serious medical conditions. This move highlights the confidence of a major institutional investor in Amgen's long-term prospects.